Treatment of drug-susceptible and drug-resistant tuberculosis

Lange Christoph G.; Brehm Thomas Theo; Chesov Dumitru; Kherabi Yousra; Guglielmetti Lorenzo

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

161

SM ISO690:2012

LANGE, Christoph G., BREHM, Thomas Theo, CHESOV, Dumitru, KHERABI, Yousra, GUGLIELMETTI, Lorenzo. Treatment of drug-susceptible and drug-resistant tuberculosis. In: ERS Monograph, 2023, vol. 2023, pp. 117-138. ISSN 2312-508X. DOI: https://doi.org/10.1183/2312508X.10024622

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

ERS Monograph

Volumul 2023 / 2023 / ISSN 2312-508X /ISSNe 2312-5098

Treatment of drug-susceptible and drug-resistant tuberculosis

DOI:https://doi.org/10.1183/2312508X.10024622

Pag. 117-138

Lange Christoph G.¹²³⁴, Brehm Thomas Theo⁵², Chesov Dumitru¹²³⁶, Kherabi Yousra⁷⁸, Guglielmetti Lorenzo⁷⁸

¹ Research Center Borstel,
² German Center for Infection Research, Tuberculosis Unit, Borstel,
³ University of Lübeck,
⁴ Baylor College of Medicine,
⁵ University Medical Center Hamburg-Eppendorf, Hamburg,
⁶ ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
⁷ Sorbonne University,
⁸ National Reference Center for Mycobacteria and resistance of mycobacteria to anti-tuberculosis drugs (CNR-MyRMA)

Disponibil în IBN: 1 octombrie 2023

Rezumat

Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid; 4-month treatment for paucibacillary TB in children; 4-month treatment for PTB in adults based on rifapentine; and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.

Cuvinte-cheie
bedaquiline, carbapenem, clofazimine, dpre1 inhibitor, ethambutol, gyrase inhibitor, isoniazid, levofloxacin, linezolid, macozinone, mmpl3 inhibitor, moxifloxacin, pretomanid, pyrazinamide, pyrifazimine, qcrb inhibitor, quinoline derivative, rifampicin, rifapentine, tedizolid, telacebec, unclassified drug